Bevacizumab (BEV) continued beyond first progression in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with BEV + chemotherapy (CT): Biomarker findings from ML18147.

Authors

Stefan Kubicka

District Clinic Reutlingen

Stefan Kubicka , Roger Von Moos , Richard Greil , Javier Sastre , Pia Osterlund , Dirk Arnold , Thierry André , Eric Van Cutsem , Thomas Mueller , Irmarie Reyes-Rivera , Jaafar Bennouna

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study.

First Author: T. Hansen

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.

First Author: Camille Sibertin-Blanc

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study.

First Author: Richard Greil

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC).

First Author: Patrick Tamukong